Loading
A phase 1/2 trial of AP402 (Part 1 Dose esclation) in advanced solid tumours, run by AP Biosciences Inc., now recruiting.
A Study of AP402 in HER2-Positive Patients With Locally or Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06669975 by AP Biosciences Inc., with 85 participants planned, started 2025-04-22 and due to reach its primary completion in 2026-12-01. Interventions recorded: AP402 (Part 1 Dose esclation) and AP402 (Part 2 Dose Expansion).
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares AP Biosciences and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/